Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients
Language English Country Switzerland Media print-electronic
Document type Journal Article
PubMed
29529610
DOI
10.1159/000487903
PII: 000487903
Knihovny.cz E-resources
- Keywords
- Circulating immune complexes, Galactose deficiency, Glycan-specific antibodies, IgA1 hinge region, Iga nephropathy, O-glycosylation,
- MeSH
- Glucocorticoids pharmacology therapeutic use MeSH
- Glycosylation drug effects MeSH
- Glomerulonephritis, IGA diagnosis drug therapy MeSH
- Immunoglobulin A blood immunology metabolism MeSH
- Antigen-Antibody Complex blood MeSH
- Humans MeSH
- Prednisone therapeutic use MeSH
- Prognosis MeSH
- Antibodies blood MeSH
- Case-Control Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Glucocorticoids MeSH
- Immunoglobulin A MeSH
- Antigen-Antibody Complex MeSH
- Prednisone MeSH
- Antibodies MeSH
BACKGROUND/AIMS: IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes. Some of them, after deposition into kidney mesangium, trigger glomerular injury. In patients with active disease nonresponding to angiotensin-converting enzyme inhibitors or angiotensin II blockers, corticosteroids are recommended. METHODS: The relationship between the corticosteroid therapy and serum levels of IgA, aberrantly O-glycosylated IgA1, IgA-containing immune complexes and their mesangioproliferative activity was analyzed in IgA nephropathy patients and disease and healthy controls. RESULTS: Prednisone therapy significantly reduced proteinuria and levels of serum IgA, galactose-deficient IgA1, and IgA-IgG immune complexes in IgA nephropathy patients and thus reduced differences in all of the above parameters between IgAN patients and control groups. A moderate but not significant reduction of mesangioproliferative potential of IgA-IgG immune complexes and IgA sialylation was detected. CONCLUSION: The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients.
References provided by Crossref.org
